The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: sulfasalazine     Quarter: 2016Q3

Total Drug/Injury Combinations: 559     Number of Pages: 28

DRUGNAME PT EventCount
SULFASALAZINE. Prerenal failure 1 view events
SULFASALAZINE. Product substitution issue 1 view events
SULFASALAZINE. Productive cough 1 view events
SULFASALAZINE. Pulmonary sarcoidosis 1 view events
SULFASALAZINE. Pyelonephritis 1 view events
SULFASALAZINE. Radicular pain 1 view events
SULFASALAZINE. Rash erythematous 1 view events
SULFASALAZINE. Rash generalised 1 view events
SULFASALAZINE. Rash macular 1 view events
SULFASALAZINE. Rectal haemorrhage 1 view events
SULFASALAZINE. Rectal polyp 1 view events
SULFASALAZINE. Red blood cell sedimentation rate 1 view events
SULFASALAZINE. Renal disorder 1 view events
SULFASALAZINE. Respiratory distress 1 view events
SULFASALAZINE. Retching 1 view events
SULFASALAZINE. Rotator cuff repair 1 view events
SULFASALAZINE. Rotator cuff syndrome 1 view events
SULFASALAZINE. Seizure 1 view events
SULFASALAZINE. Sepsis 1 view events
SULFASALAZINE. Shoulder arthroplasty 1 view events

Total Drug/Injury Combinations: 559     Number of Pages: 28

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)